A Phase 2 interventional study of Placebo and Denosumab in Low Bone Mineral Density, sponsored by Amgen. Completed. Open to female participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2013-09-18.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing denosumab in Bone Diseases, Metabolic — 1 open to participants now, 1 under way, none of them phase 3. Denosumab · Bone Diseases, Metabolic.
Among the 25 studies testing denosumab in Bone Diseases, Metabolic, this one is the 5th largest by enrollment, is the only one that started in 2002, is one of 3 in phase 2, and was the 1st registered.
663 studies on the registry are indexed under Bone Diseases, Metabolic; 95 are open to participants now.
Browse Bone Diseases, Metabolic studies →1 of the 25 studies testing denosumab in Bone Diseases, Metabolic is open now, in 1 country. Recruiting first, the newest first:
Capital Medical University · Sites in China
Ages 18–100
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.
This study: Up to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 14 · Phase 4 4
First in 2002; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 412 is above the median of 60 across 510 interventional studies indexed under Bone Diseases, Metabolic.
Median enrollment 100 across the 25 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 25 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
23 studies in Bone Diseases, Metabolic by Amgen: none open now, none under way, none of them phase 3. Of 23 finished, 21 (91%) have results posted.
Among the 23 studies in Bone Diseases, Metabolic by Amgen, this one is the 7th largest by enrollment, is the only one that started in 2002, is one of 4 in phase 2, and was the 1st registered.
Amgen’s Bone Diseases, Metabolic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing denosumab in Bone Diseases, Metabolic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 23 in Bone Diseases, Metabolic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the effect of denosumab treatment compared with placebo over 12 months on bone mineral density (BMD) of the lumbar spine in postmenopausal women with low BMD. The clinical hypothesis is that denosumab subcutaneous injections administered every 3 or 6 months for 12 months will significantly increase lumbar spine bone mineral density and will be well tolerated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
administration of the following medications within the 6 months before the enrollment date
administration of the following medications within the 3 months before the enrollment date
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.
Drug: Placebo
Participants received denosumab 6 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
Drug: Denosumab
Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
Drug: Denosumab
Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.
Drug: Denosumab
Participants received denosumab 14 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
Drug: Denosumab
Participants received denosumab 60 mg SC every 6 months until Month 42.
Drug: Denosumab
Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
Drug: Denosumab
Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.
Drug: Denosumab
Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.
Drug: Alendronate
Placebo subcutaneous injection
Denosumab for subcutaneous injection
Also known as: AMG 162, Prolia
Alendronate 70 mg tablets
Also known as: Fosamax
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and Month 12
Serum CTX Percent Change From Baseline at Month 12
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and Month 12
Urine NTX/Creatinine Percent Change From Baseline at Month 12
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and Month 12
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Alendronate Arm
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and Month 12
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 24 months
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 36 months
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 42 months
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 48 months
Serum CTX Percent Change From Baseline at Month 24
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 24 months
Serum CTX Percent Change From Baseline at Month 36
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 36 months
Serum CTX Percent Change From Baseline at Month 42
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 42 months
Serum CTX Percent Change From Baseline at Month 48
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 48 months
Urine NTX/Creatinine Percent Change From Baseline at Month 24
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 24 months
Urine NTX/Creatinine Percent Change From Baseline at Month 36
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 36 months
Urine NTX/Creatinine Percent Change From Baseline at Month 42
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 42 months
Urine NTX/Creatinine Percent Change From Baseline at Month 48
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 48 months
Total Hip Bone Mineral Density Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 12 months
Total Hip Bone Mineral Density Percent Change From Baseline at Month 24
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 24 months
Total Hip Bone Mineral Density Percent Change From Baseline at Month 36
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 36 months
Total Hip Bone Mineral Density Percent Change From Baseline at Month 42
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 42 months
Total Hip Bone Mineral Density Percent Change From Baseline at Month 48
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 48 months
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 12 months
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 24 months
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 36 months
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 42 months
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 48 months
Total Body Bone Mineral Density Percent Change From Baseline at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 12 months
Total Body Bone Mineral Density Percent Change From Baseline at Month 24
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 24 months
Total Body Bone Mineral Density Percent Change From Baseline at Month 36
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 36 months
Total Body Bone Mineral Density Percent Change From Baseline at Month 42
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 42 months
Total Body Bone Mineral Density Percent Change From Baseline at Month 48
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 48 months
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 12 months
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 24 months
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 36 months
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 42 months
Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline and 48 months
First Subject Enrolled: 11-May-2002 Last Subject Enrolled: 30-Apr-2003
| Milestone | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 46 | 44 | 44 | 41 | 54 | 47 | 42 | 47 | 47 |
| Completed | 29 | 29 | 24 | 19 | 36 | 39 | 25 | 31 | 30 |
| Not completed | 17 | 15 | 20 | 22 | 18 | 8 | 17 | 16 | 17 |
| Withdrew: Physician decision | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 2 | 2 | 2 | 3 | 2 | 1 | 2 | 1 | 3 |
| Withdrew: Withdrawal by subject | 11 | 8 | 11 | 13 | 14 | 6 | 12 | 9 | 10 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Disease progression | 1 | 0 | 0 | 3 | 0 | 0 | 0 | 4 | 0 |
| Withdrew: Ineligibility determined | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 5 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Withdrew: Noncompliance | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M |
|---|---|---|---|---|---|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms | -0.81 ± 0.48 | 4.41 ± 0.50 | 4.71 ± 0.50 | 6.69 ± 0.54 | 3.03 ± 0.43 | 4.55 ± 0.47 | 5.52 ± 0.49 | 5.07 ± 0.47 |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Serum CTX Percent Change From Baseline at Month 12 | -4.699 (-20.74 to 28.3) | -61.366 (-74.42 to -41.92) | -77.989 (-87.02 to -55.37) | -87.238 (-90.53 to -71.25) | -12.054 (-38.48 to 10.69) | -70.757 (-81.47 to -55.78) | -78.617 (-85.85 to -60.95) | -84.107 (-90.70 to -77.85) | -72.603 (-81.72 to -59.55) |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Urine NTX/Creatinine Percent Change From Baseline at Month 12 | 24.300 (-23.06 to 39.84) | -40.018 (-49.76 to -6.38) | -54.688 (-66.80 to -23.33) | -60.652 (-73.16 to -46.40) | -2.027 (-20.30 to 10.84) | -36.523 (-54.67 to -16.06) | -51.256 (-67.31 to -22.17) | -58.502 (-70.55 to -29.84) | -45.409 (-59.96 to -22.74) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
| Percent change | Alendronate 70 mg |
|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Alendronate Arm | 4.59 ± 0.45 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24 | -1.25 ± 0.68 | 7.42 ± 0.69 | 7.21 ± 0.68 | 8.83 ± 0.76 | 3.94 ± 0.60 | 7.19 ± 0.62 | 7.31 ± 0.67 | 7.86 ± 0.65 | 6.09 ± 0.63 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36 | -1.80 ± 0.82 | 8.57 ± 0.80 | 9.17 ± 0.89 | 1.94 ± 0.94 | 7.99 ± 0.72 | 9.04 ± 0.74 | 10.63 ± 0.82 | 0.85 ± 0.72 | 4.70 ± 0.78 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42 | 1.09 ± 1.70 | 7.21 ± 2.13 | 10.04 ± 1.86 | 5.06 ± 2.13 | 9.46 ± 1.24 | 9.59 ± 1.40 | 9.99 ± 1.93 | 1.06 ± 1.80 | 6.51 ± 1.51 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48 | -2.39 ± 1.11 | 9.35 ± 1.09 | 9.93 ± 1.20 | 9.03 ± 1.33 | 10.10 ± 0.96 | 10.34 ± 0.96 | 11.76 ± 1.13 | 2.50 ± 1.07 | 4.54 ± 1.06 |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Serum CTX Percent Change From Baseline at Month 24 | -5.940 (-23.22 to 20.61) | -50.687 (-73.73 to -27.21) | -74.078 (-84.96 to -52.32) | -83.985 (-89.66 to -74.02) | -8.467 (-24.02 to 25.84) | -68.437 (-81.80 to -44.39) | -80.460 (-89.31 to -43.68) | -85.680 (-90.94 to -78.32) | -69.386 (-79.82 to -52.04) |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Serum CTX Percent Change From Baseline at Month 36 | -16.577 (-28.96 to -0.29) | -62.298 (-81.94 to -42.09) | -53.643 (-82.23 to -34.04) | 56.286 (21.35 to 73.85) | -57.500 (-75.77 to -23.56) | -54.418 (-72.02 to -12.53) | -45.057 (-81.69 to -11.29) | 72.135 (34.18 to 136.00) | -33.982 (-56.86 to -21.93) |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Serum CTX Percent Change From Baseline at Month 42 | -16.279 (-31.66 to 18.31) | -63.543 (-83.99 to -38.15) | -40.827 (-85.17 to -13.72) | -62.334 (-88.37 to -27.85) | -46.408 (-80.65 to -32.46) | -57.255 (-74.60 to -23.04) | -56.377 (-77.35 to -20.98) | 33.999 (0.15 to 49.68) | -46.743 (-58.94 to -26.14) |
Serum C-Telopeptide (CTX). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Serum CTX Percent Change From Baseline at Month 48 | -14.561 (-33.09 to 6.61) | -40.016 (-80.76 to 0.11) | -34.999 (-78.25 to -7.84) | -52.656 (-78.86 to -5.25) | -39.899 (-73.80 to -9.78) | -51.494 (-78.57 to -14.62) | -36.480 (-70.12 to -18.54) | 7.067 (-17.06 to 31.25) | -43.724 (-56.28 to -14.07) |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Urine NTX/Creatinine Percent Change From Baseline at Month 24 | 14.422 (-5.30 to 56.37) | -19.699 (-51.71 to 1.61) | -37.691 (-60.65 to -4.19) | -49.907 (-68.26 to -20.43) | 2.134 (-15.60 to 45.10) | -32.303 (-54.06 to 15.35) | -37.001 (-72.15 to 11.74) | -47.105 (-76.14 to -24.75) | -44.482 (-59.46 to -8.98) |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Urine NTX/Creatinine Percent Change From Baseline at Month 36 | 0.508 (-21.60 to 11.89) | -33.294 (-56.03 to -3.63) | -47.752 (-58.74 to -16.01) | 82.910 (32.79 to 108.70) | -44.301 (-58.12 to -15.68) | -36.874 (-57.37 to -5.32) | -27.174 (-56.30 to 25.52) | 70.997 (24.80 to 125.90) | -15.627 (-40.75 to 15.42) |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Urine NTX/Creatinine Percent Change From Baseline at Month 42 | -18.102 (-31.05 to 30.83) | -40.741 (-60.82 to -12.95) | -40.043 (-65.63 to -9.12) | -58.893 (-67.49 to -14.26) | -47.188 (-69.64 to -25.46) | -39.269 (-64.25 to -4.97) | -46.674 (-63.98 to -9.33) | 26.277 (-16.99 to 88.12) | -33.102 (-53.10 to -19.07) |
Urinary N-telopeptide (uNTX)/Creatinine. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Urine NTX/Creatinine Percent Change From Baseline at Month 48 | -21.064 (-36.94 to 32.77) | -23.311 (-62.33 to 11.43) | -38.002 (-67.11 to -15.91) | -50.864 (-80.48 to -9.49) | -46.128 (-64.44 to -14.07) | -40.375 (-70.06 to -0.46) | -41.998 (-70.45 to -6.62) | 7.884 (-35.02 to 72.97) | -32.198 (-59.36 to 6.68) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Total Hip Bone Mineral Density Percent Change From Baseline at Month 12 | -0.56 ± 0.37 | 2.89 ± 0.38 | 2.45 ± 0.39 | 3.32 ± 0.42 | 1.94 ± 0.33 | 3.56 ± 0.36 | 2.53 ± 0.38 | 2.33 ± 0.36 | 2.11 ± 0.35 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Total Hip Bone Mineral Density Percent Change From Baseline at Month 24 | -1.92 ± 0.44 | 4.04 ± 0.45 | 3.55 ± 0.44 | 5.03 ± 0.50 | 2.62 ± 0.39 | 4.96 ± 0.40 | 3.67 ± 0.44 | 4.18 ± 0.43 | 3.27 ± 0.41 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Total Hip Bone Mineral Density Percent Change From Baseline at Month 36 | -2.84 ± 0.60 | 4.79 ± 0.58 | 4.41 ± 0.65 | -1.23 ± 0.68 | 4.31 ± 0.52 | 5.83 ± 0.54 | 4.33 ± 0.60 | -1.43 ± 0.53 | 0.93 ± 0.57 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Total Hip Bone Mineral Density Percent Change From Baseline at Month 42 | -1.96 ± 1.16 | 5.01 ± 1.43 | 3.98 ± 1.28 | 2.37 ± 1.46 | 4.54 ± 0.85 | 6.34 ± 0.98 | 4.70 ± 1.32 | -2.67 ± 1.23 | 2.98 ± 1.03 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Total Hip Bone Mineral Density Percent Change From Baseline at Month 48 | -3.52 ± 0.65 | 5.45 ± 0.63 | 4.03 ± 0.70 | 3.86 ± 0.77 | 4.82 ± 0.56 | 6.06 ± 0.56 | 4.99 ± 0.66 | -1.37 ± 0.62 | 1.17 ± 0.62 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12 | -1.97 ± 0.50 | 0.89 ± 0.52 | 0.40 ± 0.53 | 1.10 ± 0.55 | 0.94 ± 0.46 | 1.29 ± 0.48 | 1.07 ± 0.50 | 1.09 ± 0.51 | -0.53 ± 0.47 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24 | -2.78 ± 0.56 | 1.31 ± 0.57 | 0.62 ± 0.58 | 1.30 ± 0.63 | 2.48 ± 0.52 | 1.89 ± 0.51 | 1.48 ± 0.56 | 0.81 ± 0.56 | -0.78 ± 0.55 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36 | -3.64 ± 0.63 | 1.99 ± 0.60 | 1.06 ± 0.69 | 1.05 ± 0.71 | 2.08 ± 0.55 | 2.69 ± 0.55 | 1.92 ± 0.62 | 0.12 ± 0.57 | -0.95 ± 0.61 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42 | -6.59 ± 3.00 | 1.00 ± 3.26 | 0.82 ± 2.92 | -3.91 ± 3.39 | 1.29 ± 2.14 | -0.87 ± 2.93 | 0.02 ± 5.00 | 0.59 ± 2.52 | -3.32 ± 3.95 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48 | -4.67 ± 0.75 | 1.04 ± 0.73 | 1.42 ± 0.84 | 1.77 ± 0.91 | 1.74 ± 0.66 | 1.71 ± 0.65 | 1.37 ± 0.75 | -0.94 ± 0.74 | -2.67 ± 0.75 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Total Body Bone Mineral Density Percent Change From Baseline at Month 12 | -0.21 ± 0.46 | 1.82 ± 0.45 | 1.80 ± 0.46 | 2.74 ± 0.51 | 0.55 ± 0.41 | 2.51 ± 0.43 | 1.78 ± 0.46 | 2.08 ± 0.44 | 1.51 ± 0.44 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Total Body Bone Mineral Density Percent Change From Baseline at Month 24 | -1.64 ± 0.53 | 2.59 ± 0.54 | 2.91 ± 0.53 | 4.44 ± 0.62 | 0.89 ± 0.49 | 2.57 ± 0.49 | 3.00 ± 0.53 | 2.75 ± 0.53 | 1.50 ± 0.52 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Total Body Bone Mineral Density Percent Change From Baseline at Month 36 | -1.61 ± 0.94 | 3.14 ± 0.88 | 3.04 ± 0.98 | 2.34 ± 1.09 | 2.04 ± 0.83 | 2.80 ± 0.80 | 2.59 ± 0.94 | -0.29 ± 0.83 | 4.55 ± 0.94 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Total Body Bone Mineral Density Percent Change From Baseline at Month 42 | 1.61 ± 1.76 | 1.90 ± 3.71 | 4.05 ± 1.70 | 8.85 ± 3.07 | 3.72 ± 1.97 | 4.92 ± 1.83 | 3.79 ± 3.63 | -0.75 ± 1.50 | 2.85 ± 2.67 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Total Body Bone Mineral Density Percent Change From Baseline at Month 48 | -2.54 ± 0.99 | 3.68 ± 0.98 | 3.38 ± 1.07 | 3.76 ± 1.27 | 3.42 ± 0.86 | 3.43 ± 0.87 | 3.68 ± 1.03 | -0.29 ± 0.96 | 4.49 ± 1.00 |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 12 calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12 | -4.609 (-26.46 to 30.31) | -62.716 (-77.57 to -47.64) | -60.098 (-76.61 to -41.34) | -70.256 (-80.58 to -55.16) | -39.474 (-64.97 to -13.73) | -65.215 (-77.11 to -51.79) | -61.979 (-74.25 to -50.61) | -67.634 (-75.90 to -50.19) | -61.059 (-69.89 to -46.08) |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 24 calculated using ((Month 24 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24 | 16.464 (-20.18 to 52.94) | -41.225 (-65.61 to -22.04) | -47.597 (-69.11 to -16.28) | -57.905 (-66.41 to -22.36) | -22.350 (-44.05 to 0.50) | -43.448 (-62.70 to -18.28) | -50.176 (-64.82 to -23.14) | -48.833 (-71.34 to -27.38) | -48.778 (-58.87 to -25.77) |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 36 calculated using ((Month 36 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36 | 1.955 (-28.21 to 45.67) | -39.012 (-66.11 to -12.10) | -56.021 (-69.45 to -21.31) | 22.343 (-0.27 to 49.28) | -47.500 (-63.87 to -32.19) | -42.541 (-64.46 to -24.35) | -47.418 (-57.70 to -22.78) | 61.747 (14.65 to 101.28) | -8.209 (-40.84 to 7.80) |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 42 calculated using ((Month 42 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42 | 1.288 (-25.01 to 51.68) | -40.182 (-65.62 to -11.21) | -40.819 (-64.78 to -6.13) | -52.684 (-67.62 to -34.69) | -53.763 (-62.49 to -28.55) | -44.892 (-62.36 to -25.45) | -48.303 (-59.51 to -18.60) | 17.841 (4.18 to 82.99) | -22.069 (-41.00 to 8.92) |
Bone specific alkaline phosphatase (BSAP). Percent change from Baseline to Month 48 calculated using ((Month 48 value - Baseline value) / Baseline value ) x 100.
| Percent change | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48 | 18.122 (-28.72 to 59.58) | -34.727 (-56.34 to 3.83) | -45.779 (-60.49 to 9.42) | -47.770 (-60.61 to -30.76) | -46.286 (-57.67 to -24.26) | -34.361 (-59.73 to -9.38) | -42.653 (-61.39 to -17.29) | 21.053 (8.00 to 54.55) | -17.891 (-27.39 to 12.52) |
Collected over 48 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 5/46 (10.9%) | 43/46 (93.5%) |
| Denosumab 6 mg Q3M | — | 7/43 (16.3%) | 38/43 (88.4%) |
| Denosumab 14 mg Q3M | — | 13/44 (29.5%) | 39/44 (88.6%) |
| Denosumab 30 mg Q3M | — | 9/40 (22.5%) | 35/40 (87.5%) |
| Denosumab 14 mg Q6M | — | 7/53 (13.2%) | 44/53 (83%) |
| Denosumab 60 mg Q6M | — | 5/47 (10.6%) | 42/47 (89.4%) |
| Denosumab 100 mg Q6M | — | 9/41 (22%) | 38/41 (92.7%) |
| Denosumab 210 mg Q6M | — | 6/46 (13%) | 41/46 (89.1%) |
| Alendronate 70 mg | — | 8/46 (17.4%) | 42/46 (91.3%) |
| Event | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Angina pectorisCardiac disorders | 1/46 | 2/43 | 0/44 | 0/40 | 0/53 | 0/47 | 0/41 | 2/46 | 0/46 |
| Breast cancer in situNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/46 | 0/43 | 2/44 | 0/40 | 0/53 | 0/47 | 0/41 | 0/46 | 0/46 |
| Non-cardiac chest painGeneral disorders | 0/46 | 0/43 | 1/44 | 0/40 | 1/53 | 0/47 | 0/41 | 0/46 | 2/46 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/46 | 1/43 | 0/44 | 0/40 | 2/53 | 0/47 | 0/41 | 0/46 | 2/46 |
| Acute coronary syndromeCardiac disorders | 0/46 | 0/43 | 0/44 | 1/40 | 0/53 | 0/47 | 0/41 | 0/46 | 0/46 |
| Atrial fibrillationCardiac disorders | 0/46 | 0/43 | 0/44 | 1/40 | 0/53 | 0/47 | 1/41 | 0/46 | 1/46 |
| Coronary artery diseaseCardiac disorders | 0/46 | 0/43 | 0/44 | 1/40 | 0/53 | 1/47 | 0/41 | 0/46 | 0/46 |
| PneumoniaInfections and infestations | 0/46 | 0/43 | 0/44 | 1/40 | 0/53 | 0/47 | 0/41 | 0/46 | 0/46 |
| Fibula fractureInjury, poisoning and procedural complications | 0/46 | 0/43 | 0/44 | 1/40 | 0/53 | 0/47 | 1/41 | 0/46 | 0/46 |
| Tibia fractureInjury, poisoning and procedural complications | 0/46 | 0/43 | 0/44 | 1/40 | 0/53 | 0/47 | 1/41 | 0/46 | 0/46 |
| Event | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg |
|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 11/46 | 15/43 | 10/44 | 8/40 | 13/53 | 16/47 | 8/41 | 18/46 | 14/46 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 14/46 | 7/43 | 13/44 | 9/40 | 12/53 | 11/47 | 10/41 | 12/46 | 8/46 |
| Back painMusculoskeletal and connective tissue disorders | 6/46 | 8/43 | 13/44 | 5/40 | 10/53 | 8/47 | 10/41 | 9/46 | 7/46 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 8/46 | 6/43 | 6/44 | 7/40 | 11/53 | 7/47 | 5/41 | 13/46 | 7/46 |
| NasopharyngitisInfections and infestations | 7/46 | 11/43 | 9/44 | 4/40 | 4/53 | 11/47 | 11/41 | 10/46 | 6/46 |
| DyspepsiaGastrointestinal disorders | 3/46 | 5/43 | 5/44 | 1/40 | 12/53 | 6/47 | 6/41 | 4/46 | 12/46 |
| BronchitisInfections and infestations | 5/46 | 2/43 | 1/44 | 10/40 | 4/53 | 3/47 | 1/41 | 5/46 | 4/46 |
| HypertensionVascular disorders | 2/46 | 4/43 | 8/44 | 5/40 | 12/53 | 5/47 | 10/41 | 4/46 | 5/46 |
| Influenza like illnessGeneral disorders | 5/46 | 4/43 | 4/44 | 3/40 | 10/53 | 11/47 | 6/41 | 3/46 | 7/46 |
| NauseaGastrointestinal disorders | 2/46 | 3/43 | 6/44 | 6/40 | 6/53 | 5/47 | 3/41 | 9/46 | 10/46 |
| Age Continuous(Years) | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 63.7 ± 9.1 | 62.8 ± 8.6 | 62.3 ± 6 | 61.2 ± 8.5 | 61.4 ± 8.1 | 63.1 ± 8.1 | 64.9 ± 8.2 | 60.5 ± 7.8 | 62.8 ± 8.2 | 62.5 ± 8.1 |
| Sex: Female, Male(Participants) | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 46 | 44 | 44 | 41 | 54 | 47 | 42 | 47 | 47 | 412 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Denosumab 6 mg Q3M | Denosumab 14 mg Q3M | Denosumab 30 mg Q3M | Denosumab 14 mg Q6M | Denosumab 60 mg Q6M | Denosumab 100 mg Q6M | Denosumab 210 mg Q6M | Alendronate 70 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| White or Caucasian | 37 | 33 | 42 | 36 | 49 | 39 | 37 | 42 | 40 | 355 |
| Black or African American | 0 | 1 | 1 | 2 | 1 | 1 | 3 | 0 | 3 | 12 |
| Hispanic or Latino | 8 | 8 | 1 | 3 | 3 | 5 | 2 | 5 | 4 | 39 |
| Asian | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 4 |
| Japanese | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
No study locations are listed for this record.
The record gives a start of May 2002, a primary completion of Apr 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 3 years 3 months after primary completion. A results delay was requested in Nov 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab